))
MET-Amplified Lung Cancer: A New Target for XALKORI?
Manage episode 153141033 series 1082357
Content provided by cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.
307 episodes
Share
